57 studies found for:    "Adrenocortical carcinoma"
Show Display Options
Rank Status Study
21 Completed Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu
Conditions: Advanced Adult Primary Liver Cancer;   Anaplastic Thyroid Cancer;   Bone Metastases;   Carcinoma of the Appendix;   Distal Urethral Cancer;   Fallopian Tube Cancer;   Gastrinoma;   Glucagonoma;   Inflammatory Breast Cancer;   Insulinoma;   Liver Metastases;   Localized Unresectable Adult Primary Liver Cancer;   Lung Metastases;   Male Breast Cancer;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Metastatic Gastrointestinal Carcinoid Tumor;   Metastatic Parathyroid Cancer;   Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter;   Newly Diagnosed Carcinoma of Unknown Primary;   Occult Non-small Cell Lung Cancer;   Pancreatic Polypeptide Tumor;   Primary Peritoneal Cavity Cancer;   Proximal Urethral Cancer;   Pulmonary Carcinoid Tumor;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Primary Liver Cancer;   Recurrent Anal Cancer;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Carcinoma of Unknown Primary;   Recurrent Cervical Cancer;   Recurrent Colon Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Esophageal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Recurrent Gastric Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Parathyroid Cancer;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Recurrent Small Intestine Cancer;   Recurrent Squamous Cell Carcinoma of the Larynx;   Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity;   Recurrent Squamous Cell Carcinoma of the Nasopharynx;   Recurrent Squamous Cell Carcinoma of the Oropharynx;   Recurrent Thyroid Cancer;   Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter;   Recurrent Urethral Cancer;   Recurrent Vaginal Cancer;   Recurrent Vulvar Cancer;   Skin Metastases;   Small Intestine Adenocarcinoma;   Somatostatinoma;   Stage III Adenoid Cystic Carcinoma of the Oral Cavity;   Stage III Adrenocortical Carcinoma;   Stage III Bladder Cancer;   Stage III Cervical Cancer;   Stage III Colon Cancer;   Stage III Endometrial Carcinoma;   Stage III Esophageal Cancer;   Stage III Follicular Thyroid Cancer;   Stage III Gastric Cancer;   Stage III Malignant Testicular Germ Cell Tumor;   Stage III Mucoepidermoid Carcinoma of the Oral Cavity;   Stage III Ovarian Epithelial Cancer;   Stage III Pancreatic Cancer;   Stage III Papillary Thyroid Cancer;   Stage III Prostate Cancer;   Stage III Rectal Cancer;   Stage III Renal Cell Cancer;   Stage III Salivary Gland Cancer;   Stage III Squamous Cell Carcinoma of the Larynx;   Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage III Squamous Cell Carcinoma of the Nasopharynx;   Stage III Squamous Cell Carcinoma of the Oropharynx;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Anal Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Anal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IV Adrenocortical Carcinoma;   Stage IV Anal Cancer;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Colon Cancer;   Stage IV Endometrial Carcinoma;   Stage IV Esophageal Cancer;   Stage IV Follicular Thyroid Cancer;   Stage IV Gastric Cancer;   Stage IV Mucoepidermoid Carcinoma of the Oral Cavity;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Pancreatic Cancer;   Stage IV Papillary Thyroid Cancer;   Stage IV Prostate Cancer;   Stage IV Rectal Cancer;   Stage IV Renal Cell Cancer;   Stage IV Salivary Gland Cancer;   Stage IV Squamous Cell Carcinoma of the Larynx;   Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity;   Stage IV Squamous Cell Carcinoma of the Nasopharynx;   Stage IV Squamous Cell Carcinoma of the Oropharynx;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Thyroid Gland Medullary Carcinoma;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer;   Urethral Cancer Associated With Invasive Bladder Cancer;   WDHA Syndrome
Interventions: Biological: recombinant interleukin-12;   Biological: ABI-007/carboplatin/trastuzumab
22 Recruiting Evaluation of Side Effects of Mitotane
Condition: Adrenocortical Carcinoma
Intervention:
23 Terminated Possible New Therapy for Advanced Cancer
Condition: Adrenocortical Carcinoma
Intervention: Drug: IL-13-PE
24 Unknown  Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Condition: Adrenocortical Carcinoma
Intervention: Drug: MITOTANE
25 Completed Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
Conditions: Adrenocortical Carcinoma;   Breast Cancer;   Colorectal Cancer;   Gastrointestinal Cancer;   Kidney Cancer;   Liver Cancer;   Melanoma (Skin);   Ovarian Cancer;   Pancreatic Cancer;   Sarcoma
Interventions: Biological: colloidal gold-bound tumor necrosis factor;   Other: electron microscopy;   Other: pharmacological study;   Procedure: conventional surgery
26 Completed Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy
Conditions: Adrenal Tumor;   Adrenocortical Carcinoma
Intervention: Drug: 123I-Iodometomidate
27 Unknown  Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer
Condition: Adrenocortical Carcinoma
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1
28 Completed Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
Conditions: Adrenocortical Carcinoma;   Breast Cancer;   Colorectal Cancer;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: doxorubicin hydrochloride;   Drug: suramin
29 Completed Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
Conditions: Adrenocortical Carcinoma;   Brain and Central Nervous System Tumors;   Head and Neck Cancer;   Liver Cancer;   Malignant Mesothelioma;   Pheochromocytoma;   Sarcoma
Interventions: Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: tamoxifen citrate;   Procedure: conventional surgery;   Radiation: radiation therapy
30 Recruiting Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield
Conditions: Adrenal Incidentaloma;   Adrenocortical Carcinoma
Intervention:
31 Completed Studying Genes in Samples From Younger Patients With Adrenocortical Tumor
Condition: Adrenocortical Carcinoma
Interventions: Genetic: DNA methylation analysis;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: nucleic acid sequencing;   Genetic: polymorphism analysis
32 Completed Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
Conditions: Adrenocortical Carcinoma;   Gastrointestinal Carcinoid Tumor;   Kidney Cancer;   Neuroblastoma;   Retinoblastoma;   Sarcoma
Interventions: Biological: Seneca Valley virus-001;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Other: pharmacological study
33 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
34 Recruiting Adrenal Tumors - Pathogenesis and Therapy
Conditions: Adrenal Tumors;   Adrenocortical Carcinoma;   Cushing Syndrome;   Conn Syndrome;   Pheochromocytoma
Intervention:
35 Active, not recruiting Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging
Conditions: Adrenocortical Carcinoma;   Localized Resectable Neuroblastoma;   Precancerous Condition
Interventions: Procedure: computed tomography;   Procedure: 3-Tesla magnetic resonance imaging;   Procedure: Abdominal Sonogram
36 Completed Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer
Conditions: Peritoneal Neoplasms;   Retroperitoneal Neoplasms;   Gastrointestinal Neoplasms;   Adenocarcinoma;   Neuroblastoma;   Ovarian Neoplasms;   Sarcoma;   Adrenocortical Carcinoma;   Wilms Tumor;   Rhabdomyosarcoma;   Desmoplastic Small Round Cell Tumor
Interventions: Drug: CHPP of Cisplatin;   Procedure: Abdominal Surgery
37 Completed
Has Results
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
Conditions: Adult Rhabdomyosarcoma;   Adult Synovial Sarcoma;   Childhood Hepatoblastoma;   Childhood Synovial Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Adrenocortical Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive;   Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Retinoblastoma;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Biological: cixutumumab;   Other: laboratory biomarker analysis
38 Completed Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
Conditions: Childhood Central Nervous System Germ Cell Tumor;   Childhood Extragonadal Germ Cell Tumor;   Childhood Hepatoblastoma;   Childhood Hepatocellular Carcinoma;   Childhood High-grade Cerebral Astrocytoma;   Childhood Low-grade Cerebral Astrocytoma;   Childhood Malignant Ovarian Germ Cell Tumor;   Childhood Malignant Testicular Germ Cell Tumor;   Childhood Teratoma;   Recurrent Adrenocortical Carcinoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Colon Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Nasopharyngeal Cancer;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer
Intervention: Drug: oxaliplatin
39 Not yet recruiting Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Conditions: Adrenal Cortex Carcinoma;   Adult Alveolar Soft Part Sarcoma;   Adult Clear Cell Sarcoma of Soft Parts;   Adult Hepatocellular Carcinoma;   Adult Rhabdomyosarcoma;   Adult Soft Tissue Sarcoma;   Childhood Alveolar Soft Part Sarcoma;   Childhood Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Childhood Hepatocellular Carcinoma;   Childhood Rhabdomyosarcoma;   Childhood Soft Tissue Sarcoma;   Childhood Solid Neoplasm;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adult Hepatocellular Carcinoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Hepatocellular Carcinoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Relapsed Solid Neoplasm;   Renal Cell Carcinoma;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
40 Completed Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
Condition: Carcinoma, Adrenal Cortical
Interventions: Drug: Etoposide;   Drug: Doxorubicin;   Drug: Cisplatin;   Drug: Streptozotocin;   Drug: Mitotane

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-57) Show next page of results    Last Page
Indicates status has not been verified in more than two years